Professor David Lalloo

Dean of Clinical Sciences and International Public Health; Chair in Tropical Medicine; Director Wellcome Trust Tropical Centre

Areas of interest

Clinical trials in resource poor settings. Travel medicine.

Background

Having undergone initial training in Newcastle upon Tyne, David Lalloo trained in General (Internal) Medicine, Infectious Diseases and Tropical Medicine, spending three years in Papua New Guinea. He undertook clinical and laboratory research in Oxford before moving as Senior Lecturer to the Liverpool School of Tropical Medicine in 1999. Since then he has focused on clinical trials in the tropics, particularly in HIV related infections, malaria and envenoming. He currently has collaborations and studies in a number of countries including Uganda, Malawi, Sri Lanka and Vietnam. He holds an appointment as Honorary Consultant at the Royal Liverpool University Hospital and is Clinical Director of the Tropical Medicine Directorate

Teaching

Lectures and small group teaching on the Liverpool DTM and H. Lectures to many other groups nationally.

Research 

Clinical trials in resource poor settings. Particular interest in HIV and opportunistic infections. Recently completed a large MRC funded trial on primary prophylaxis against cryptococcal disease in Uganda and studies on meningitis in Malawi. Currently running studies of safety of repeated dosing of artemisinin combination therapy in children.(www.actconsortium.org/). Clinical trials in envenoming are ongoing in Sri Lanka: recently completed a large study assessing prophylaxis against antivenom reactions and commencing a national epidemiological study

Students

Currently supervising 11 PhD and MD students 

Director

Wellcome Trust Liverpool Tropical Centre and Wellcome Trust Clinical PhD programme http://www.liverpoolwttc.org.uk/

Other relevant expertise, professional memberships etc.

  • Chair: Health Protection Agency Advisory Committee on Malaria Prevention in Travellers
  • Member: Steering Committee of the National Travel Health Network and Centre (NATHNAC)
  • Member: MRC Infection and Immunity Board
  • Member: MRC Ethics Policy Advisory Committee
  • Member: MRC Global Health Group
  • Member: Wellcome Trust/MRC/DfID Clinical Trials PaneI
  • External Examiner: DTM and H, Royal College of Physicians, London,
  • Chairman of a number of international Data Monitoring Committees

Current Projects

  • 2003 to 2006

    DfID: Lapdap studies (joint with University of Liverpool)

    Grant £665,804

  • 2003 to 2008 | Uganda

    Medical Research Council: Trial of fluconazole prophylaxis against cryptococcal meningitis in HIV infected Ugandans

    Grant: £1,589,000

  • 2006 to 2008 | Malawi

    Meningitis Research Foundation: Randomised trial of glycerol adjuvant therapy in adult bacterial meningitis in Malawi

    Grant: £90,390

  • 2007 to 2009 | Malawi

    Wellcome Trust: Pharmacology of Nevirapine in Malawian Patients: (Joint with UoL)

    Grant: £438,229

  • 2006 to 2010

    DfiD: Addressing the balance of the burden of AIDS: (joint with D Haran, A Medina Lara, S Theobald)

    Grant: £3,750,000

  • 2008 to 2011 | Malawi

    Gates Foundation: Programmatic implementation of ACTs in Malawi (joint PI with Dr Terlouw):

    Grant: £1,695,381

  • 2008 to 2011 | Uganda and Malawi

    EDCTP: Strengthening of long term clinical and laboratory research capacity in Uganda and Malawi to prepare for HIV vaccine trials

    Grant: £168,597

  • 2009 to 2012

    Wellcome Trust: Wellcome Centre for Research in Clinical Tropical Medicine (joint with Profs Heyderman and UoL)

    Grant: £462,535

  • 2009 to 2012

    Gates Foundation: Pharmacovigilance of ACT (joint PI with UoL)

    Grant: £600,516

  • 2010 to 2012 | Africa

    Wellcome Trust: Surveillance for influenza in the context of pandemic H1N1 in an African population with a high burden of HIV, Malaria and Malnutrition (Co-applicant)

    Grant: £360,600

  • 2011 to 2016

    MRC: A phase III randomised controlled trial of oral fluconazole plus flucytosine versus amphotericin B-based therapy for cyptococcal disease (Co-applicant)

    Grant: £2,619,486

  • 2012 to 2016

    MRC/DfID/Wellcome Trust: A multi-centre randomized placebo controlled trial of dexamethasone to improve the outcome of cryptococcal meningitis (Co-applicant)

    Grant: £4,593,228

Publications

  • Selected Publications

    AjdukiewiczKMB, Cartwright K, Scarborough M, Mwambene J, Goodson P, Molyneux ME, Zijlstra EE, French N, Whitty CJM, Lalloo DG. A double blind, randomised controlled trial of glycerol adjuvant therapy in adult bacterial meningitis in a high HIV seroprevalence setting in Malawi. Lancet Infectious Diseases 2011 (4):293-300

    Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A , Kenya Mugisha N, Grosskurth H , Kamali A, Lalloo DG. Primary prophylaxis of cryptococcal disease using fluconazole in HIV positive Ugandan adults - a double blind, randomised, placebo controlled trial. Lancet Infectious Diseases. 2011 Dec;11(12):933-41

    De Silva HA, Pathmeswaran A, Jayamanne S, Samarakone SMSB, Hittharage A, Kalupahana R, Ratnathilake A, Uluwatte W, Ranasinha CD, Aronson JK, Armitage J, Lalloo DG, De Silva HJ. Promethazine, hydrocortisone, and low-dose adrenaline (alone and in combination) in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double blind, placebo-controlled trial. PLOS Medicine. 2011 May; 8(5):e1000435

    Wakeham K; Parkes-Ratanshi R; Watson V; Ggayi, A; K Saye; Lalloo DG. Co-administration of fluconazole increases nevirapine concentrations in HIV infected Ugandans. Journal of Antimicrobial therapy 2010 65(2):316-9

    Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG. Snake envenoming: a disease of poverty. PLoS Negl Trop Dis 3(12) Dec 2009: e569

    Mujica Mota R, Medina Lara A, Kunkwenzu, E, Lalloo DG. Health seeking behaviour after fever onset in a malaria-endemic area of Malawi. Am J Trop Med Hyg 2009 81(6)935–943

    Bell D, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes D, Molyneux M, Ward SA, Winstanley PA, Lalloo DG.Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria. Malaria Journal2009 8:204

    Lalloo DG, Hill DR. Preventing malaria in travellers. BMJ. 2008 Jun 14;336(7657):1362-6

    Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioloi L, Lalloo DG, de Silva HJ (2008). Estimation of the global burden of snakebite. PLoS Medicine 2008 Vol. 5, No. 11, e218.

    Scarborough M, Gordon SB, Whitty CJM, French N, Njalale Y, Chitani A, Peto TEA, Lalloo DG, Zijlstra EE. Steroids for bacterial meningitis in adults with HIV in sub-Saharan Africa. New Eng J Med 2007: 357:2441-50

    Bell DJ, Kapitao Y, Sikwese R, Oosterhout J, Lalloo DG. Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. JAIDS 2007 15;45(5):560-3

    Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell DA, Bannister BA. UK malaria treatment guidelines. J Infect. 2007 Feb;54(2):111-21

    Chiodini P, Hill D, Lalloo D, Lea G, Walker E, Whitty C, Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom. Health Protection Agency. January 2007

    Lalloo DG, Olukoya P, Olliaro P. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect Dis. 2006 (12):780-93.

    Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006 Jun;6(6):361-73

    De Silva HA, Fonseka M, Pathmeswaran A, Alahakone D, Ratnatilake GA, Gunatilake SB, Ranasinha CD, Lalloo DG, Aronson JK, de Silva HJ. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet. 2003 Jun 7;361(9373):1935-1938